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LOCALIZATION OF AMPA-SELECTIVE EXCITATORY 
AMINO ACID RECEPTOR SUBUNITS IN IDENTIFIED 
POPULATIONS OF STRIATAL NEURONS 
S. J. TALLAKSEN-GREENE and R. L. ALBIN* 
Department of Neurology, University of Michigan, Ann Arbor, MI 48104-1687, U.S.A. 
AMtract--Two-color immunofluorescence histochemistry and immunohistochemistry in combination 
with retrograde tract-tracing techniques were used to examine the relationship of ct-amino-3-hydroxy-5- 
methyl-4-isoxazole proprionic acid (AMPA)-selective glutamate receptor subunits (GIuR1, GluR2/3/4c 
and GIuR4) to identified populations of striatal projection neurons and interneurons. The majority of 
striatonigral and striatopallidal neurons were double-labeled for GluR2/3/4c. These findings were 
confirmed using calbindin to label matrix projection neurons. In contrast, immunostaining of the GIuRI 
subunit was not observed to co-localize with any striatal projection neurons. Striatal interneurons 
immunostained for parvalbumin were also labeled by antibodies directed against the GIuR1 subunit. 
Approximately 50% of parvalbumin neurons also contained GluR2/3/4c. Somatostatin immunoreactivity 
did not co-localize with either the GluRl or GluR2/3/4c subunits. GluR4-immunoreactive neurons were 
not observed in striatum. 
This study demonstrates that AMPA-selective glutamate receptors are differentially localized on 
subpopulations of striatal neurons and interneurons. These findings suggest that discrete striatal neuron 
populations may express different AMPA receptor subunit combinations which may account for their 
functional specificity. 
The striatum is the major afferent component of the 
basal ganglia and receives as its main input a massive 
excitatory amino acidergic (EAAergic) projection 
from the neocortex and allied areas. Corticostriatal 
inputs are topographically organized based on re- 
gional and laminar origin and by site of termin- 
ation. 25'43 However, the relationship between 
EAAergic input to specific pools of striatal projection 
neurons and interneurons is not completely under- 
stood. Organization of the striatum is based on 
segregation of input systems, segregation of output 
systems and compartmentalization of striatal neurons 
(see Ref. 25 for review). It has been postulated that 
changes in the specific function of subpopulations 
of striatal neurons may account for the variety of 
clinical manifestations associated with basal ganglia 
disease. 2 The majority (90-95%) of striatal neurons 
are medium spiny GABAergic output neurons, which 
are segregated into "patch" (striosome) and "matrix" 
compartments. In the rat, the smaller patch com- 
partment is enriched in #-opiate receptors 46 and 
5'-nucleotidase: 9 Neurochemical markers distributed 
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preferentially within the matrix include acetyl- 
cholinesterase, tyrosine hydroxylase, calbindin-D28k, 
somatostatin and cytochrome oxidaseY Several 
populations of striatal interneurons have been 
classified based on morphology and the differential 
expression of neuractive substances, including large, 
aspiny cholinergic interneurons, medium aspiny 
interneurons expressing both parvalbumin and 
GABA, and interneurons co-containing somato- 
statin, neuropeptide Y and NADPH-diaphorase, a 
nitric oxide synthase. Rodent striatal output neurons 
are segregated into two main populations on the 
basis of their target structure, substantia nigra and 
globus pallidus. Striatonigral neurons are further 
characterized by their expression of substance P and 
dynorphin, whereas striatopallidal neurons are distin- 
guished by expression of the peptide enkephalin. 
Differential distribution of receptors among stri- 
atal projection neurons and interneurons may play a 
role in the regulation of striatal function. Segregation 
of receptors in striatum is known to occur, although 
the extent to which segregation is maintained, 
particularly with regard to dopamine receptors, is 
controversial: 2 Striatonigral neurons have been 
described as enriched in D l dopamine 29 and N- 
methyl-D-aspartate (NMDA) receptors, 53 whereas 
striatopallidal neurons have been shown to exhibit 
enrichment in D 2 dopamine 3° and A2a adenosine 
receptors: s Autoradiographic and immunohisto- 
chemical studies have demonstrated differences 
in EAA receptors between striosome and matrix 
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compar tmen t s  in h u m a n  TM and monkey  4~ str iatum. 
Subpopula t ions  of  striatal  project ion neurons  and 
in te rneurons  have been shown to have a differential 
expression of  muscarinic  cholinergic receptor sub- 
types )  
Four  major  subtypes of  funct ional  EAA receptors 
have been identified; N M D A ,  ~-amino-3-hydroxy-5-  
methyl-4-isoxazole propr ionic  acid (AMPA) ,  
metabo t rop ic  quisqualate  and  kainate  receptors. Re- 
cently, a new "de l t a"  class of  E A A  receptor has been 
identified, bu t  no funct ional  profile has been deter- 
mined. 4° Molecular  cloning strategies have revealed 
that  multiple subuni ts  of  each receptor subtype ap- 
pear  to exist, including four major  A M P A  receptor 
subuni ts  (GIuR1-GIuR4 ;  see Ref. 23 for review). 
EAA receptor subtype subunits ,  like E A A  receptor 
subtypes, show a differential d is t r ibut ion in brain,  
and the subuni t  configurat ion of  ionotropic  EAA 
receptor subtypes has been shown to influence their  
pharmacologica l  and  electrophysiological proper-  
ties. ~2'33'44'51 Since E A A  receptor subunit  configurat ion 
is likely to be an  impor t an t  factor  in the media t ion  of  
striatal  EAA neurot ransmiss ion,  we examined the 
relat ionship of  AMPA-select ive  EAA receptor sub- 
units to identified popula t ions  of  striatal  project ion 
neurons  and  in te rneurons  using two-color  immuno-  
fluorescence his tochemistry and  immunohis tochem-  




Eight male Sprague-Dawley rats (200-225 g; Spartan 
Labs, Hastings, MI) were anesthetized with ketamine- 
xylazine (10:3, 1 ml/kg, i,m.) and placed in a stereotaxic 
apparatus. Fluoro-Gold (FG; Fluorochrome, Inc., Engle- 
wood, CO; 0.2 #1 of a 2% solution in 0.9% saline) was 
pressure injected into either substantia nigra or globus 
pallidus using coordinates taken from the atlas of Paxinos 
and Watson. 4s For substantia nigra, coordinates were: AP 
-5.4,  ML +1.8, DV -8 .2  from bregma. For globus 
pallidus, the needle was tilted 16 ° medially to avoid pene- 
trating the striatum and coordinates were AP -1.0,  ML 
+0.5, DV -7.0.  Animals were allowed to survive for 12 
days following FG injection. 
Tissue processing 
In all studies, the animals were deeply anesthetized with 
pentobarbitol (100 mg/kg, i.p.) and perfused through the 
ascending aorta with 100 ml of 0.1 M phosphate buffer (PB), 
followed by 400 ml of 2% paraformaldehyde in PB (pH 7.4). 
The brains were removed, blocked and placed in fresh 
fixative for 1-3 h. A modification of the method of Barthel 
and Raymond 3 was used to achieve cryoprotection adequate 
for cutting 4-6/~m cryostat sections. Briefy, the brains were 
transferred through a series of graded sucrose solutions 
made up in PB (5, 7.5, 12.5, 15 and 20% ; rotating at 
4°C for a minimum of 1 h at each step, or until the brains 
sank). The brains were placed in a 2:1 solution of 
20% sucrose PB-Tissue-Tek OCT embedding compound 
(Miles, Kankakee, IL) for 45 min, transferred to embedding 
molds, surrounded by fresh PB:OCT, frozen over liquid 
nitrogen and stored at -70°C until processed for immuno- 
histochemistry. 
lmmunohistochemistry 
Eight FG-injected and four untreated brains were pro- 
cessed for one-color or two-color immunofluorescence histo- 
chemistry, respectively. All antibodies and fluorochromes 
were made up in I% normal donkey serum4).3% Triton 
X-100 in PB. Rinses were in PB (×3,  15min each). For 
immunofluorescence staining of glutamate receptor subunits 
in FG-labeled tissue, 4 # m  coronal sections were cut 
through the rostral striatum using a cryostat microtome. 
The tissue was rinsed and incubated in 4% normal donkey 
serum in 0.3% Triton X-100-PB (1 h, room temperature). 
Normal donkey serum was blotted off and affinity-purified 
antiserum was pipetted onto tissue sections (RH9, specific 
for GIuR1, RH27, recognizing GIuR2, 3 and 4c or RH25, 
specific for GIuR4, gifts from Dr Richard Huganir, 
0.5ltg/ml, overnight at 4°C). The tissue was rinsed and 
incubated in biotin-labeled donkey anti-rabbit immuno- 
globulin G (1:2000, l h, room temperature; Jackson 
lmmunoResearch, West Grove, PA). Sections were rinsed 
and incubated in cyanine 3.18 conjugated to streptavidin 
(l :  300, 1 h, room temperature; Jackson ImmunoResearch). 
After three washes, the sections were coverslipped using a 
fade-retarding mounting medium. 34 For two-color immuno- 
fluorescence staining of glutamate receptor subunits and 
either somatostatin, calbindin or parvalbumin, 4 #m cryo- 
stat sections were processed according to the same protocol 
described above, except that (i) the primary antibody sol- 
ution contained a mixture of rabbit anti-glutamate receptor 
antiserum (0.5#g/ml) and either rat anti-somatostatin 
(1:50, Accurate Chemicals, Westbury, NY), mouse anti- 
calbindin (1:200, Sigma Chemical Co., St. Louis, MO) or 
mouse anti-parvalbumin (1:200, Sigma Chemical Co.), and 
(ii) the fluorochrome solution contained a mixture of cya- 
nine 3.18 conjugated to streptavidin (1:300) and fluorescein- 
labeled donkey anti-rat or anti-mouse immunoglobulin G 
( 1 : 200, Jackson ImmunoResearch). 
Quantification 
Sections were examined under epifluorescence illumi- 
nation using a Nikon Microphot-SA microscope equipped 
with the following filters. FG: 330-380 nm excitor; 435 nm 
barrier filter. Cyanine 3.18:510-560 nm excitor; 610 nm 
barrier filter. Fluorescein: 450-490 excitor; 520-560 nm 
barrier filter. For the purpose of analysis, the striatum was 
divided into four quadrants: dorsomedial (DM), dorsolat- 
eral (DL), ventromedial (VM) and ventrolateral (VL). The 
density of single- and double-labeled cells was determined 
using a grid reticle inserted in the eyepiece of the microscope 
and a x 20 objective. Matrix and patch compartments 
were distinguished by the presence or absence of calbindin 
immunoreactivity, respectively. Average densities for each 
experimental paradigm were established using measure- 
ments taken from four animals; from each rat, three sections 
were examined; for each area in a section, the density of 
single- and double-labeled cells per 0.17mm 2 was estab- 
lished. In studies examining the density of AMPA receptor 
subtypes in patch and matrix compartments, the area of 
each compartment in a quadrant was often less than 
0.17 mm 2 in a single section. In these instances, the density 
of fluorescently-labeled cells was determined by measuring 
the entire area of each compartment and recording the 
total number of labeled neurons. These numbers were 
then normalized to express the density as the number of 
single- and double-labeled neurons per 0.17 mm 2. 
RESULTS 
Fluoro-Gold tract tracing and glutamate receptor 
immunohistochemistry 
Dense labeling of str iatonigral  neurons  was ob- 
served unilaterally in all quadran t s  of the s t r ia tum 
AMPA receptors in striatum 
Table 1. Combined glutamate receptor immunohistochemistry and Fluoro-Gold 
labeling of striatal projection neurons 
+ GluR- + GluR- - GluR- 
Striatal immunoreactive immunoreactive immunoreactive 
quadrant - FG + FG + FG 
GluR-1 immunohistochemistry and FG labeling of striatonigral neurons 
DL 5+0  0 _ 0  71__+6 
DM 6+1 0__+0 78+8 
VL 4 + 0  0+ 0  58+ 15 
VM 4 + 0  0__+0 46+ 16 
GluR-2/3/4c immunohistochemistry and FG labeling of striatonigral neurons 
DL 37__+4 62+2 4-1- 1 
DM 39__+3 73+5 4__ 1 
VL 53_+6 61 _+6 2_+ 1 
VM 43+7 53-+5 2-+1 
GIuR-1 immunohistochemistry and FG labeling of striatopallidal neurons 
DL 4_+0 0 + 0  38_+ 16 
DM 5_+ I 0__+0 139-+9 
VL 4 + 0  0+ 0  20-+ 19 
VM 4-+0 0+ 0  116-+5 
GluR-2/3/4c immunohistochemistry and FG labeling of striatopallidal neurons 
DL 85-+ 13 20+7 1 -+ 1 
DM 10+2 101 +4 5+2 
VL 99 -+ 16 15 ___ 14 I + 1 
VM 11 __+6 95+0 4-+ 1 
The data are expressed as the number of neurons (mean + S.E.M.) single- or 
double-labeled by immunohistochemistry and/or FG, n = 4 rats. The counts 
were derived from examining areas of 0.17 mm 2 per region. 
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following injection of FG into the medial substantia 
nigra (Table 1). FG injection into the globus pallidus 
resulted in dense labeling of striatopallidal neurons in 
the unilateral DM and VM quadrants and relatively 
few retrogradely-labeled cells in the DL and VL 
quadrants (Table 1). Neurons immunostained for 
GIuR1 or GIuR2/3/4c appeared to be homogeneously 
distributed throughout the striatum (Table 1). No 
GluR4-immunoreactive neurons were observed in the 
striatum. 
In all quadrants, the majority (/>94%) of FG- 
labeled striatonigral (Fig. 1 B) or striatopallidal (Fig. 
2B) neurons were double-labeled for GluR2/3/4c 
(Table 1). In contrast, immunostaining of the GIuR1 
subunit was not observed to co-localize with any 
FG-labeled striatonigral (Fig. 1A) or striatopallidal 
(Fig. 2A) neurons (Table 1). 
Immunohistochemical double-labeling 
GIuR1 and GluR2/3/4c AMPA receptor subunits 
appeared to be evenly distributed throughout the 
striatum. We did not observe any differences in the 
density of either GIuRI- or GluR2/3/4c-immuno- 
reactive neurons between patch and matrix compart- 
ments (data not shown). Calbindin immunoreactivity 
was observed throughout the matrix in all but the DL 
striatal quadrant (Table 2). In DM, VM and VL 
striatum, the majority (92, 88 and 93%, respectively) 
of GluR2/3/4c-immunoreactive neurons were double- 
labeled for calbindin (Table 2, Fig. 3B). Virtually no 
co-existence of GIuRI and calbindin was observed 
(Table 2, Fig. 3A). 
Striatal neurons immunostained for parvalbumin 
were also labeled by antibodies directed against 
the GIuR 1 subunit (Table 3, Fig. 4A). Approximately 
50% of parvalbumin neurons also contained 
GluR2/3/4c (Table 3, Fig. 4B). 
Somatostatin immunoreactivity did not co-localize 
with either the GIuR1 or GluR2/3/4c subunits (Table 
4, Fig. 5). 
DISCUSSION 
We have shown previously that EAA receptor 
subtypes are expressed on striatonigral projection 
neurons. 5a In the present study, we have extended 
these findings demonstrating that subunits of AMPA- 
selective EAA receptors are differentially localized 
on subpopulations of striatal interneurons and pro- 
jection neurons. We used anti-peptide antibodies 
to examine the relationship of AMPA-selective EAA 
receptor subunits to specific striatal neuron popu- 
lations identified by (i) retrograde labeling with FG 
as striatonigral or striatopallidal projection neurons, 
(ii) calbindin immunostaining as matrix projection 
neurons, (iii) parvalbumin immunostaining as parv- 
albumin/GABAergic interneurons, or (iv) somato- 
statin immunostaining as somatostatin/neuropeptide 
Y/NADPH-diaphorase (nitric oxide synthase)-con- 
taining medium aspiny interneurons. The characteriz- 
ation and specificity of the GluR antisera have been 
described previously. 9,1°.42 The antisera to EAA recep- 
tor subunits are both directed against C-terminal 
peptides common to both "flip and flop" splice 
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Fig. 1. (A) Fluorescence photomicrographs of the same tissue section demonstrating that striatal neurons 
immunoreactive for GluR1 (left panel) are distinct from striatonigral neurons labeled with FG (right 
panel). Arrowheads indicate GluRl-immunoreactive neurons that are not labeled with FG. (B) Paired 
fluorescence photomicrographs demonstrating that striatonigral neurons express GluR2/3/4c subunits. 
Arrows point to FG-labeled striatonigral neurons (right panel) double-labeled for GluR2/3/4c (left panel). 
variants. The GluRI antibody is specific for the 
GluRI subunit, while the GluR2/3/4c antibody rec- 
ognizes an epitope conserved on GIuR2, GIuR3 and 
GluR4c subunits. In the present study, GluR2/3/4c 
results are specific for GIuR2/3 as in situ studies have 
shown that the GluR4c subtype is expressed only in 
the cerebellum. 36 Our results indicate that the GluRI 
subunit is selectively expressed by interneurons con- 
taining parvalbumin. A portion (~50%)  of parv- 
albumin interneurons also stain for GluR2/3/4c. The 
notion that striatal parvalbumin interneurons are not 
a homogeneous cell population is further supported 
by the work of Kawaguchi, 35 who has described 
two types of striatal parvalbumin interneuron 
based on dendritic field size and axon arborization 
pattern. Most (>/88%) striatal projection neurons, 
identified by either retrograde labeling with F G  or 
calbindin immunostaining, were double-labeled with 
GluR2/3/4c. These findings raise the possibility that 
subpopulations of striatal neurons may be differen- 
tially regulated by EAA receptors displaying unique 
subunit configurations. 
Multi-color fluorescence microscope techniques 
were employed in these studies because they allow the 
visualization of multiple fluorochromes in a single 
tissue section and, with the appropriate filters, it is 
AMPA receptors in striatum 513 
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Fig. 2. (A) Fluorescence photomicrographs illustrating that striatopallidal neurons labeled with FG (right 
panel) are separate from striatal neurons immunoreactive for GluR1 (left panel). Arrowheads indicate 
single-labeled structures. (B) Expression of  GluR2/3/4c subunits on striatopallidal neurons demonstrated 
by striatal neurons immunoreactive for GluR2/3/4c and retrogradely labeled with FG following an 
injection of  tracer in the ipsilateral globus pallidus (arrows). 
Table 2. Immunohistochemical staining of  AMPA-selective glutamate receptor 
subunits and calbindin in striatal matrix 
+ GIuR- + GIuR- - GluR- 
immunoreactive immunoreactive immunoreactive 
Striatal - Calbindin- + Calbindin- + Calbindin- 
quadrant immunoreactive immunoreactive immunoreactive 
GIuR-I subunit 
DM 2_+0 0 _ 0  102__+8 
VL 2 + 0  1 + 0  118+15 
VM 3 + 0  0 + 0  9 7 +  12 
GluR-2/3/4c subunit 
DM 8 +  1 9 8 +  14 2 +  1 
VL 1 5 + 4  108+ 15 6 + 4  
VM 8__+3 101 + 12 3__+2 
The data are expressed as the number of  neurons (mean + S.E.M.) single- or 
double-labeled by immmunohistochemistry, n = 4 rats. The counts were 
derived from examining areas of  0.17 mm 2 per region. 
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Fig. 3. Dark-field photomicrographs of striatal sections showing simultaneous two-color immunottuores- 
cence staining for GIuR subunits  (left panels) and calbindin (right panels). (A) Arrowheads point to GIuR l- 
immmunoreact ive neurons (left panel) that  do not stain for calbindin (right panel). The section shown 
in B demonstrates  that co-existence of  GluR2/3/4c and calbindin immunoreactivity is common  (arrows). 
Table 3. Immunohistochemical  staining of AMPA-selective glutamate receptor 
subunits and paravalbimin striatum 
+ GIuR- + GluR- - GluR- 
immunoreactive immunoreactive immunoreactive 
Striatal - Parvalbumin- + Parvalbumin- + Parvalbumin- 
quadrant  immunoreactive immunoreactive immunoreactive 
GIuR- 1 subunit  
DL 1 _+0 7 +  1 0 _ 0  
DM  2 + 0  5 +  1 0__+0 
VL 2 + 0  5+_1 0 + 0  
VM 1 + 0  6 + 1  0 + 0  
GluR-2/3/4c subunit  
DL 106+ 13 24- I 3 + 1  
DM 1 1 2 _ 1 7  1_+0 3_+ I 
VL 114__+5 2 +  1 2+_1 
VM 115-t-16 1_+0 2 + l  
The data are expressed as the number  of  neurons (mean + S.E.M.) single- or 
double-labeled by immunohistochemistry,  n = 4 rats. The counts were derived 
from examining areas of  0.17 m m  2 per region. 
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Fig. 4. Fluorescence photomicrographs illustrating co-existence o f  parvalbumin- (A and B, right panels) 
and GluRI -  (left panel) or GluR2/3/4c-immunoreactivity (B, left panel) in striatum. Double-labeled 
neurons are indicated by arrows. Arrowheads point to single-labeled neurons. 
Table 4. Immunohistochemical  staining of  AMPA-selective glutamate receptor 
subunits  and somatostat in in str iatum 
+ GIuR- + GluR- - GluR- 
immunoreactive immunoreactive immunoreactive 
Striatal - Somatostatin- + Somatostatin- + Somatostatin- 
quadrant  immunoreactive immunoreactive immunoreactive 
GIuR- 1 subunit  
DL 6 + 1  0 + 0  3 + 0  
DM  9 +  I 0 + 0  3 ___0 
VL 4 + 0  0 + 0  3 + 0  
VM 74- 1 0__+0 34 -0  
GluR-2/3/4c subunit  
DL  124__+ 15 0_+0 34 -0  
D M  128__+ 14 0 4 - 0  2 + 0  
VL 132+ 14 0__+0 34 -0  
VM 1454-20 0 4 - 0  34 -0  
The data are expressed as the number  of  neurons (mean + S.E.M.) single- or 
double-labeled by immunohistochemistry,  n = 4 rats. The counts were derived 
from examining areas of  0.17 m m  2 per region. 
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Fig. 5. Paired fluorescence photomicrographs of sections through the striatum demonstrating segregation 
of neurons stained for somatostatin (right panels) and either GIuRI (A, left panel) or GluR2/3/4c (B, left 
panel) subunits. Arrowheads point to single-labeled neurons. 
easy to distinquish between different colored labels. 
In striatum, AMPA receptor subtypes are expressed 
abundantly in the neuropil and in neuronal peri- 
karya. 42 In these studies, we used thin (4 #m) cryostat 
sections to maximize visualization of perikaryal stain- 
ing. However, we cannot exclude the possibility that 
some neurons might express receptor without having 
significant perikaryal epitope. 
The predominant EAAergic input to the striatum 
is from the cerebral cortex, with other probable 
EAA inputs from the amygdala, hippocampus and 
intralaminar thalamic nuclei. 43 Electrophysiological 
studies indicate that cortically evoked excitatory 
postsynaptic potentials in striatum are mediated 
largely by non-NMDA receptors, jW'~5 although 
NMDA receptors may be recruited under depolar- 
izing conditions.~5 Several striatal cell types have been 
shown to receive direct synaptic input from the 
cerebral cortex, including parvalbumin interneurons 
(in primate) 39 and neuropeptide Y interneurons (in 
rodent). 54 
Autoradiographic, 2°,28,53 immunohistochemical 4L42 
and in situ hybridization 24 studies have shown that 
NMDA, AMPA, kainate and metabotropic gluta- 
mate receptors subtypes are inhomogeneously distri- 
buted in striatum. The majority of striatal EAA 
binding sites, including AMPA binding sites, are 
thought to be localized postsynaptically on striatal 
neurons. 2°'28'53 AMPA binding sites have been 
reported on striatal projection neurons. 28'53 
Recently, the production of anti-peptide antibodies 
to EAA receptor subunits has improved the cellular 
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resolution of receptor localization. Several studies 
have identified EAA receptor subunits co-localized 
with neurochemical markers used to identify subsets 
of neurons. In rat, 42 but not in monkeyfl  GluR1 
subunits have been reported to co-localize extensively 
with cholinergic interneurons. GluRI has also been 
reported to co-localize with a small population of 
NADPH-diaphorase-positive neurons in rat stria- 
tum. 42 NADPH-diaphorase has been shown to be 
co-contained with neuropeptide Y and somatostatin 
in medium aspiny striatal interneurons. However, 
using somatostatin as a marker, we did not observe 
any co-localization of GIuRI with somatostatin/ 
neuropeptide Y/NADPH-diaphorase (nitric oxide 
synthase) interneurons. This discrepancy may be 
methodological, since the two studies used separate 
immunohistochemical procedures and different 
means of visualizing histochemical staining (fluor- 
escence vs chromagens). Alternatively, GluR1 may 
co-localize with a population of NADPH-diaphorase 
neurons that do not contain somatostatin, although 
previous studies suggest that the co-existence of 
NADPH-diaphorase and somatostatin in striatal 
interneurons may be complete. GluR1 immuno- 
reactivity has been described previously in a sparse 
population of medium spiny neurons. 42 Using cal- 
bindin as a marker, we observed very few medium 
spiny neurons immunostained for GluRI (Table 1). 
Martin e t  al.  42 have reported that medium-sized spiny 
neurons are the only striatal cell type to express 
GluR2/3/4c. However, in addition to extensive 
GluR2/3/4c-immunostaining of striatai projection 
neurons, we observed co-localization of GluR2/3/4c 
with some parvalbumin neurons, which have been 
classified as medium aspiny interneurons. 26 These 
findings are similar to what has been described in 
the monkeyfl  We observed a small population of 
calbindin-stained neurons that did not express 
GluR2/3/4c. These cells may be matrix projection 
neurons 25 or may belong to a much smaller popu- 
lation of calbindin neurons that have recently been 
characterized as medium aspiny neurons with 
NADPH-diaphorase activity. 7 
Excessive stimulation of EAA receptors is known 
to play a role in certain acute neurodegenerative 
changes seen following brain trauma, such as hy- 
poxia/ischemia and hypoglycemia. ~6 EAA-induced 
"excitotoxicity" has also been proposed as a 
causative factor in chronic neurological diseases, such 
as Huntington's disease, Parkinson's disease and 
Alzheimer's disease, where the susceptibility of dis- 
crete subpopulations of neurons could be determined 
by the subunit composition of EAA receptors ex- 
pressed. Neurotoxicity studies suggest that receptor 
distribution may only partially explain neuronal 
vulnerability to EAAs. For  example, somatostatin/ 
neuropeptide Y/NADPH-diaphorase (nitric oxide 
synthase) interneurons have been shown to be selec- 
tively vulnerable to AMPA toxicity, 5,6 although 
the present study and others 42 indicate that AMPA 
receptor subtypes are not expressed on the majority 
of these interneurons. 
In Huntington's disease, the prominent striatal 
atrophy characteristic of the disease is believed to be 
due to the sequential degeneration of specific sub- 
populations of striatal projection n e u r o n s .  1'17'21'22'31'47 
Subtype-specific EAA agonists acting at NMDA, 
kainate and AMPA receptors all induce loss of 
striatal projection neurons. However, NMDA ago- 
nists appear to most closely replicate the pattern 
of cell loss and interneuron sparing observed in 
Huntington's disease. 4'6 These findings support 
the theory that NMDA-mediated neurotoxicity is 
involved in the pathogenesis of Huntington's disease, 
although Dure e t  al.  19 have recently reported a 
uniform reduction in binding to all three ionotropic 
EAA receptor subtypes (NMDA, AMPA and 
kainate) in the striatum of Huntington's disease 
patients compared to control subjects. 
In Parkinson's disease, the principal neurochemical 
defect is the loss of striatal dopamine, although recent 
evidence suggests that an increase in glutamatergic 
activity in the subthalamic nucleus may play 
an important, if not essential, role in the develop- 
ment of parkinsonian symptoms/2'27 Interactions 
between glutamate and dopamine systems are 
known to occur in striatum. Anatomically, there 
is a "triadic" arrangement between dopaminergic 
terminals synapsing on the neck of dendritic spines 
of striatal neurons in close proximity to cortico- 
striate terminals synapsing on the tips of spines. 5° 
Several groups have suggested that EAA antagonists 
could be used to manipulate basal ganglia function 
of Parkinson's disease patients (for review, see Ref. 
27). Suppression of glutamatergic neurotransmission 
has been shown to produce antiparkinsonian effects. 
NMDA antagonists have been shown to produce 
an increase in motor behavior similar to that 
induced by dopamine agonists ~4,37 and to potentiate 
the effects of L-DOPA in monoamine-depleted rats 37. 
Similarly, AMPA antagonists have been shown to 
stimulate locomotor activity and decrease muscular 
rigidity in monoamine-depleted rats and to reduce 
tremor and improve akinesia and posture in 
l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine.treated 
monkeys. 38 Development of subtype-specific drugs 
may prove to be useful in the treatment of 
Parkinson's disease. 
CONCLUSIONS 
The results of the present study confirm and extend 
the findings of previous reports demonstrating that 
AMPA-selective EAA receptors are differentially lo- 
calized on subpopulations of striatal neurons and 
interneurons. The differential distribution of EAA 
receptor subtypes may prove to be an important 
factor in the selective vulnerability of striatal neurons 
in basal ganglia disease. Knowledge of the cellular 
localization of striatal EAA receptor subtypes is 
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impor t an t  to our  unders tand ing  of  how E A A  neuro-  
t ransmission is mediated in specific striatal  neuron  
populat ions.  Such in format ion  may  provide insights 
into the etiology and /o r  pa thophysio logy of  basal 
ganglia disease and  lead to the deve lopment  of sub- 
type-specific therapeut ic  agents useful in slowing the 
progression of  or amel iorat ing disease symptoms.  
Fur the r  studies will be needed to determine the full 
complement  of  EAA receptor subuni ts  expressed by 
specific striatal  neuron  subpopulat ions .  
Acknow&dgements--We thank Dr Richard Huganir for 
providing the antisera for glutamate receptor subunit local- 
ization and Dr Lee Martin for his technical advice. These 
studies were supported by NIH grant NS 19613 (to R.L.A.) 
and a grant from the Huntington's Disease Society of 
America (to S.T.G.). 
REFERENCES 
1. Albin R. L., Reiner A., Anderson K. D., Penney J. B. and Young A. B. (1990) Striatal and nigral neuron subpopulations 
in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27, 
357 365. 
2. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 
12, 36f~375. 
3. Barthel L. K. and Raymond P. A. (1990) Improved method for obtaining 3-micron cryosections for immunocyto- 
chemistry. J. Histochem. Cytochem. 38, 1383 1388. 
4. Bazzett T. J., Becker J. B., Kaatz K. W. and Albin R. L. (1993) Chronic intrastriatal dialytic administration of 
quinolinic acid produces selective neural degeneration. Expl Neurol. 120, 177 185. 
5. Beal M. F., Ferrante R. J., Swartz K. J. and KowaU N. W. (1991) Chronic quinolinic acid lesions in rats closely resemble 
Huntington's disease. J. Neurosci. 11, 1649-1659. 
6. Beal M. F., Kowall N. W., Swartz K. J., Ferrante R. J. and Martin J. B. (1989) Differential sparing of 
somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse, 31, 38~17. 
7. Bennett B. D. and Bolam J. P. (1993) Two populations of calbindin D28k-immunoreactive neurones in the striatum 
of the rat. Brain Res. 610, 305-310. 
8. Bernard V., Normand E. and Bloch B. (1992) Phenotypical characterization of the rat striatal neurons expressing 
muscarinic receptor genes. J. Neurosci. 12, 3591-3600. 
9. Blackstone C. D., Levey A. I., Martin L. J., Price D. L. and Huganir R. L. (1992) Immunological detection of glutamate 
receptor subtypes in human central nervous system. Ann. Neurol. 31, 680~583. 
10. Blackstone C. D., Moss S. J., Martin L. J., Levey A. I., Price D. L. and Huganir R. L. (1992) Biochemical 
characterization and localization of a non-N-methyl-D-aspartate glutamate receptor in rat brain J. Neurochem. 58, 
1118-1126. 
I 1. Calabresi P., Mercuri N. B. and Bernardi G. (1992) Activation of quisqualate metabotropic receptors reduces glutamate 
and GABA-mediated synaptic potentials in the rat striatum. Neurosci. Lett. 139, 41~44. 
12. Calabresi P., Mercuri N. B., Sancesario G. and Bernardi G. (1993) Electrophysiology of dopamine-denervated striatal 
neurons. Implication for Parkinson's disease. Brain 116, 433452. 
13. Calabresi P., Mercuri N. B., DeMurtas M. and Bernardi G. (1991) Involvement of GABA systems in feedback 
regulation of glutamate- and GABA-mediated synaptic potentials in rat neostriatum. J. Physiol. 440, 581-599. 
14. Carlsson M. and Carlsson A. (1989) Dramatic synergism between MK-801 and clonidine with respect to locomotor 
stimulatory effect in monoamine-depleted mice. J. neural Transm. 77, 65-7l. 
15. Cherubini E., Herding P. L., Lanfumey L. and Stanzione P. (1988) Excitatory amino acids in synaptic excitation of 
rat striatal neurones in vitro. J. Physiol. 400, 677~690. 
16. Choi D. W. (1992) Excitotoxic cell death. J. Neurobiol. 23, 1261 1276. 
17. Dawbarn D., Dequidt M. E. and Emson P. C. (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurones 
in Huntington's disease. Brain Res. 340, 251~60. 
18. Dure L. S. IV, Young A. B. and Penney J. B. Jr. (1992) Compartmentalization of excitatory amino acid receptors in 
human striatum. Proc. natn. Acad. Sci. 89, 7688-7692. 
19. Dure L. S. IV, Young .A.B. and Penney J. B. Jr. (1991) Excitatory amino acid binding sites in the caudate nucleus 
and frontal cortex of Huntington's disease. Ann. Neurol. 30, 785-793. 
20. Errami M. and Nieoullon A. (1988) ~-[3H]Amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid binding to rat striatal 
membranes: effects of selective brain lesions. J. Neurochem. 51, 579 586. 
21. Ferrante R. J., Beal M. F., Kowall N. W., Richardson E. P. Jr. and Martin J. B. (1987) Sparing of acetylcholinesterase- 
containing striatal neurons in Huntington's disease. Brain Res. 411, 162 166. 
22. Ferrante R. J., Kowall N. W., Beal M. F., Richardson E. P. Jr., Bird E. D. and Martin J. B. (1985) Selective sparing 
of a class of striatal neurons in Huntington's disease. Science, 230, 561-564. 
23. Gasic G. P. and Hollmann M. (1992) Molecular biology of glutamate receptors. A. Rev. Physiol..54, 507 536. 
24. Ge P., Aizawa H., Lester J., Sapp E., Aronin N., Vonsattel J.-P. and DiFiglia M. (1992) Distribution of NMDA 
receptor mRNA in rat neostriatal neurons. Soc. Neurosci. Abstr. 18, 308. 
25. Gerfen C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15, 
133-139. 
26. Gerfen C. R., Baimbridge K. G. and Miller J. J. (1985) The neostriatal mosaic: compartmental distribution of 
calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. nam Acad. Sci. U.S.A. 82, 
8780-8784. 
27. Greenamyre J. T. (1993) Glutamate~lopamine interactions in the basal ganglia: relationship to Parkinson's disease. 
J. neural Transm. 91, 255-269. 
28. Greenamyre J. T. and Young A. B. (1989) Synaptic localization of striatal NMDA, quisqualate and kainate receptors. 
Neurosci. Lett. 101, 133-137. 
29. Harrison M. B., Wiley R. G. and Wooten G. F. (1990) Selective localization of striatal D~ receptors to striatonigral 
neurons. Brain Res. 528, 317-322. 
AMPA receptors in striatum 519 
30. Harrison M. B., Wiley R. G. and Wooten G. F. (1992) Changes in D2 but not D t receptor binding in the striatum 
following a selective lesion of striatopallidal neurons. Brain Res. 59tl, 305-310. 
31. Hirsch E. C., Graybiel A. M., Hersh L. B., Duyckaerts C. and Agid Y. (1989) Striosomes and extrastriosomal matrix 
contain different amounts of immunoreactive choline acetyltransferase in human striatum. Neurosci. Lett. 96, 145-150. 
32. Hollmann M., Boulter J., Maron C., Beasley L., Sullivan J., Pecht G. and Heinemann S. (1993) Zinc potentiates 
agonist-induced currents at certain splice variants of the NMDA receptor. Neuron 10, 943-954. 
33. Hollmann M., O'Shea-Greenfield A., Rogers S. W. and Heinemann S. (1989) Cloning by functional expression of a 
member of the glutamate receptor family. Nature 342, 643~48. 
34. Johnson G. D. and Nogueira-Araujo G. M. deC. (1981) A simple method of reducing the fading ofimmunofluorescence 
during microscopy. J. immun. Meth. 43, 349-350. 
35. Kawaguchi Y. (1993) Physiological, morphological, and histochemical characterization of three classes of interneurons 
in rat neostriatum. J. Neurosci. 13, 4908~4923. 
36. Kein~inen K., Wisden W., Sommer B., Werner P., Herb A., Verdoorn T. A., Sakmann B. and Seeburg P. H. (1990) 
A family of AMPA-selective glutamate receptors. Science 2,49, 556-560. 
37. Klockgether T. and Turski L. (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in 
monoamine-depleted rats. Ann. Neurol 28, 539-546. 
38. Klockgether T., Turski L., Honore T., Zhang Z. M., Gash D. M., Kurlan R. and Greenamyre J. T. (1991) The AMPA 
receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. 
Ann. Neurol. 30, 717 723. 
39. Lapper S. R., Smith Y., Sadikot A. F., Parent A. and Bolam J. P. (1992) Cortical input to parvalbumin-immunoreactive 
neurones in the putamen of the squirrel monkey. Brain Res. 580, 215-224. 
40. Lomeli H., Sprengel R., Laurie D. J., Krhr  G., Herb A., Seeburg P. H. and Wisden W. (1993) The rat delta-I and 
delta-2 subunits extend the excitatory amino acid receptor family. Fedn. Eur. biochem. Socs Lett. 315, 318-322. 
41. Martin L. J., Blackstone C. D., Huganir R. L. and Price D. L. (1993) The striatal mosaic in primates: striosomes and 
matrix are differentially enriched in ionotropic glutamate receptor subunits. J. Neurosci. 53, 782-792. 
42. Martin L. J., Blackstone C. D., Levey A. I., Huganir R. L. and Price D. L. (1993) AMPA glutamate receptor subunits 
are differentially distributed in rat brain. Neuroscience, 53, 327-358. 
43. McGeorge A. J. and Faull R. L. M. (1989) The organization of the projection from the cerebral cortex to the striatum 
in the rat. Neuroscience 29, 503-537. 
44. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B. and Seeburg P. H. 
(1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science, 256, 1217-1221. 
45. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York. 
46. Pert C. B., Kuhar M. J. and Snyder S. H. (1976) Opiate receptor: autoradiographic localization in rat brain. Proc. natn. 
Acad. Sci. U.S.A. 73, 3729-3733. 
47. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney, J. B. and Young A. B. (1988) Differential loss of 
striatal projection neurons in Huntington disease. Proc. natn. Acad. Sci. U.S.A. 85, 5733-5737. 
48. Schiffmann S. N. and Vanderhaeghen J.-J. (1993) Adenosine A 2 receptors regulate the gene expression of striatopallidal 
and striatonigral neurons. J. Neurosci. 13, 1080-1087. 
49. Schoen S. W. and Graybiel A. M. (1992) 5'-Nucleotidase: a new marker for striosomal organization in the rat 
caudoputamen. J. comp. Neurol. 322, 566-576. 
50. Smith A. D. and Bolam J. P. (1990) The neural network of the basal ganglia as revealed by the study of synaptic 
connections of identified neurones. Trends Neurosci. 13, 259-265. 
51. Sommer B., Kein~inen K., Verdoorn T. A., Wisden W., Burnashev N., Herb A., Krhler M., Takagi T., Sakmann B. 
and Seeburg P. H. (1990) Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. 
Science, 249, 1580-1585. 
52. Surmeier D. J., Reiner A., Levine M. S. and Ariano M. A. (1993) Are neostriatal dopamine receptors co-localized? 
Trends Neurosci. 16, 299-305. 
53. Tallaksen-Greene S. J., Wiley R. G., and Albin R. L. (1992) Localization of striatal excitatory amino acid binding site 
subtypes to striatonigral projection neurons. Brain Res. 594, 165-170. 
54. Vuillet J., Kerkerian L., Kachidian P., Bosler O. and Nieoullon A. (1989) Ultrastructural correlates of functional 
relationships between nigra dopaminergic or cortical afferent fibres and neuropeptide Y-containing neurons in the rat 
striatum. Neurosci. Lett. 100, 99-104. 
(Accepted 14 January 1994) 
